Skip to main content
. 2007 Nov 14;36(1):179–188. doi: 10.1093/nar/gkm871

Figure 9.

Figure 9.

A hypothetical model of DNA-independent inhibition of NKX2.1 and FOXA1 by SMAD3. (A) In the absence of TGF-beta treatment, NKX2.1 and FOXA1 can readily bind to their cognate sites and activate transcription of the SpB promoter. (B) Treatment with TGF-beta activates SMAD3, which in turn binds through its MH domains to NKX2.1 and FOXA1 and prevents their binding to the SpB promoter. Factors I and II represent other transcription, or co-factors participating in SpB gene activation.